CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Pneumobase.it
Neurobase.it

Search results for "Pulmonary arterial hypertension"

Researchers at the University of Alberta discovered important new information they hope will lead to more effective treatments for pulmonary arterial hypertension ( PAH )--a deadly form of high blood ...


FDA ( Food and Drug Administration ) approved Revatio ( Sildenafil ) as a treatment for pulmonary arterial hypertension ( PAH ), a rare, aggressive and life-shortening vascular disease. Sildenafil i ...


A study, published in the New England Journal of Medicine ( NEJM ) showed Revatio ( Sildenafil citrate ) to be effective in treating the symptoms of pulmonary arterial hypertension ( PAH ) in adults. ...


Data from the interim analysis of the on-going PATENT-2 trial with Riociguat ( Adempas ), the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Tho ...


Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. The SERAPHIN trial has assessed the efficacy ...


Actelion has announced the results of COMPASS-2, a Phase IV, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of Bosentan ( Tracleer ) on the time to ...


A study has evaluated the effect of Macitentan ( Opsumit ) on hospitalization of patients with symptomatic pulmonary arterial hypertension ( PAH ). PAH is a progressive, life-threatening disease ofte ...


The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension are published in the European Heart Journal and the European Respiratory Journal. The document was written joint ...


Activation of the endothelin system has been demonstrated in both plasma and lung tissue of PAH ( pulmonary arterial hypertension ) patients. Although it is unclear if the increases in endothelin-1 pl ...


Phase 2 results for Ralinepag, an investigational, long-acting, orally administered prostacyclin receptor agonist under development for the treatment of pulmonary arterial hypertension ( PAH ). In t ...


In pulmonary arterial hypertension ( PAH ), combination therapy is an important treatment strategy. Although randomized controlled trial data are available to support the combination of two therapie ...


Patients with left-sided heart failure who get implanted devices to improve the pumping of their hearts may be more likely to develop heart failure on the opposite side of their hearts if they are pre ...